New AI tool to spot skin cancer to be used in NHS
The National Institute for Health and Care Excellence (Nice) said that the technology, which has been conditionally approved for the next three years, has the potential to reduce waiting times.
It comes as health experts issued a warning over sun cream ahead of the Bank Holiday weekend.
Melanoma Focus said a large proportion of Britons are frequently letting themselves burn, putting themselves at a higher risk of deadly skin cancer.
AI is being deployed to speed up the diagnosis of skin cancer and free up capacity within dermatology.
DERM assesses and classifies scans of moles or skin lesions that have been taken by a healthcare professional, after patient is referred by a GP for suspected skin cancer. pic.twitter.com/unqGj0Myv7
— Bolton NHS Foundation Trust (@boltonnhsft) April 2, 2025
The new artificial intelligence (AI) tool, DERM (Deep Ensemble for Recognition of Malignancy), works by analysing images of moles or skin lesions to see whether they are potentially cancerous.
The tool, developed by Skin Analytics, can be used by healthcare workers who use a smartphone with a high quality magnifying lens attached, also known as a dermoscopic lens, to take images of suspicious moles, or skin lesions.
The images are then uploaded on to DERM's online platform, which uses AI to analyse the images.
For patients whose moles or lesions are identified as potentially cancerous, a specialist skin doctor, known as dermatologist, will review the case and come up with a plan for the patient.
People whose moles or lesions are not suspicious are either offered reassurance and advice or can be put on a 'non-urgent pathway'.
Nice said that early evidence suggests the automated use of the tool could 'approximately halve the number of referrals to dermatologists within the urgent skin cancer pathway'.
DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety Nice
It has been 'conditionally approved' for the next three years, while further evidence is collected, Nice said.
'DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety,' said Dr Anastasia Chalkidou, healthtech programme director at Nice.
'Our evaluation shows this technology maintains diagnostic accuracy while reducing the burden on specialist dermatology services. By implementing this system within existing pathways, we can ensure patients get the right care more quickly.'
Ashley Dalton, minister for public health and prevention, said: 'By embracing the power of AI, this exciting technology could help us slash waiting times — meaning that people with suspected skin cancer get the help they need, or peace of mind, faster.'
Neil Daly, chief executive of Skin Analytics said: ''We're incredibly proud of the work we've been doing with the NHS over the last five years to achieve this recommendation from Nice. Having seen more than 165,000 patients and found more than more than 15,500 cancers since launching, we are ready to make our Class III autonomous skin cancer AI available to more UK patients.'
The British Association of Dermatologists said in a statement: 'Until further evidence is generated, the British Association of Dermatologists recommends that all patients should have some input from a dermatologist.
'Implementation of AI must be underpinned by patient safety, with a clear understanding of the benefits and limitations.'
The Association said that AI has 'the potential to transform dermatology services' but said that more real-world evidence is needed.
It comes as Melanoma Focus warned about the dangers of sunburn among Britons.
'It is essential that everyone understands the risks associated with sunburn and prioritises sun protection by using factor 30+ sunscreen, wearing a hat, seeking shade and covering up in the heat of the day,' said Susanna Daniels, chief executive of Melanoma Focus.
A poll by Melanoma Focus of 2,000 people aged 16 and over in the UK that almost half (49%) said they are sunburned at least once a year, with higher numbers reported in younger age groups.
Ms Daniels added: 'This data is extremely concerning as we know that more than five sunburns in your lifetime doubles your risk of melanoma, so burning every year has potentially long-term dangerous consequences.
'Nearly nine in 10 melanomas are preventable, yet the UK has more deaths from melanoma per year than Australia.'
The poll also found that 19% said they 'rarely' wear sun cream in the UK between May and September, 8% said they 'never' use sun cream in the UK during this period. Almost one in 10 (9%) said they never wear sun cream at all.
Reasons for avoiding sun cream in the UK included people not expecting to burn; forgetting to apply sun cream and 8% said sun cream is 'too expensive'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
an hour ago
- BBC News
Muscular dystrophy drug rejected for use by NICE
A man with a rare muscle-wasting condition said he feels "deflated" that a drug that improves his symptoms has not been approved for use on the Stephenson, from Doncaster, has myasthenia gravis and has been admitted to hospital 32 times because muscles involved in his breathing stopped since taking the drug efgartigimod, the 45-year-old has not needed to go on a ventilator once and said he had seen a "huge improvement" in his National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its "substantial" cost of more than £6,500 per infusion vial, despite it improving people's symptoms. Myasthenia gravis causes fatigue and muscle weakness, double vision, slurred speech, and difficulty with chewing, swallowing and making facial expressions."If you weigh up the cost of the drug against the hospitalisations, invasive procedures, surgeons and one-to-one care I have needed at times - I think prevention [with efgartigimod] is a cost-effective option," Mr Stephenson said."This is the first drug which has made a huge improvement and, unless you are a multimillionaire, you are not going to be able to afford to get it." 'Immense relief' Mr Stephenson was diagnosed in 2003 when, after leaving the armed forces, he began to struggle to exercise, close his eyes or smile."Food would get stuck in my throat and I would have to reach down and pull it out," he said."When I was drinking, I was choking, and water was pouring out of my nose."You worry, 'how am I going to live like this, what am I going to do?'"The father-of-four's symptoms fitted in with a recent car crash, but physiotherapists referred him to a neurologist who tested for the Stephenson said: "The diagnosis was an immense relief."If you have a chronic illness, it's good to learn about it, because you're going to be stuck with it forever."Adults who took part in a trial for efgartigimod reported regaining the ability to walk daily, dress independently, and some returned to work or education."Anybody who is on the drug at the minute can stay on it, but for new patients, it's not going to be available to them."I feel so lucky to be on it," Mr Stephenson said."I feel honoured and privileged to have been on the trial."Doctors will be able to privately prescribe the drug, also known as Vyvgart, meaning patients who can pay for it will still be able to to drug company Argenx, the price for one 400mg infusion vial is £6, number of vials used for one infusion, which Mr Stephenson said he has fortnightly, depends on the individual. 'Disheartening message' Andy Fletcher, chief executive of charity Muscular Dystrophy UK, said the decision not to approve the drug for NHS use "sends a disheartening message to those affected by rare and complex conditions"."Treatments are within their grasp, but their needs are not being prioritised," he said efgartigimod was an add-on alongside other treatments, rather than a appealed against the decision on the basis that the drug is a replacement, but NICE rejected the appeal."They got ignored and that, for everybody, was so frustrating," Mr Stephenson said."Our story should've made some sort of impact, but it feels it got bypassed and overlooked."NICE said drugs like efgartigimod replace other treatments only temporarily, providing "small benefits".A spokesperson said effective and fast-acting treatments like efgartigimod would be "welcomed" by patients, given the side effects and slow-acting nature of current treatments, but NICE could not justify the cost."The cost-effectiveness estimates [for efgartigimod] are substantially above what NICE considers an acceptable use of NHS resources," they said."We know this decision will be disappointing for people living with this debilitating condition and those who care for them."Muscular Dystrophy UK said Wales and Northern Ireland tend to follow NICE guidance, meaning patients there will most likely also be affected.A separate decision process is under way in Scotland. Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North
The Independent
10 hours ago
- The Independent
Why the NHS may never use breakthrough Alzheimer's drugs
The National Institute for Health and Care Excellence (Nice) is expected to refuse the use of Alzheimer's drugs lecanemab and donanemab on the NHS, despite their success in slowing the disease's progression. The regulator's decision will reportedly be based on cost-effectiveness, as the drugs are estimated to cost between £20,000 to £25,000, which is considered too high for the limited benefit they provide. Trials showed lecanemab can slow Alzheimer's progression by 27 per cent over 18 months by removing build-ups of the protein beta-amyloid from the brain, while donanemab teaches the body's immune cells to remove the amyloid protein. Around 70,000 adults would have been eligible for treatment if the drugs had been approved. Both drugs have UK drug licenses and are available privately, but Nice estimates that the cognitive decline slowed by donanemab is not enough to justify the cost to the NHS. Alzheimer's Research UK expressed disappointment, stating that while the treatments are not perfect, they represent a vital foundation for further scientific progress.
The Independent
21 hours ago
- The Independent
Thousands of NHS patients ‘to be denied breakthrough Alzheimer's drugs'
Breakthrough drugs that slow the progression of Alzheimer's disease will reportedly be refused for use on the NHS this week in a blow to thousands of patients. The two drugs, Lecanemab and donanemab, slow down the decline in Alzheimer's patients' ability to carry out daily activities. The drugs' success in halting the progression of Alzheimer's was heralded as a 'new era' by campaigners and researchers. However, the National Institute for Health and Care Excellence (Nice) is expected to refuse to recommend them on the NHS, according to The Sunday Times. The regulator has already issued two decisions, one in October last year and another in March, saying they would not recommend the drugs for use on the NHS. A final decision will be published on Thursday. Both drugs already have UK drug licences, making them available privately. It is estimated that around 70,000 adults in England would have been eligible for treatment if the drugs had been approved. The regulator will reportedly turn down both drugs on the grounds of cost-effectiveness, with one insider telling The Sunday Times: 'It is the end of the road for these drugs on the NHS'. Lecanemab removes build-ups of the protein beta-amyloid from the brain. Trials showed that lecanemab can slow the progression of Alzheimer's by 27 per cent over 18 months if given to someone early on in the course of their decline. Donanemab, marketed as Kisunla in the UK, teaches the body's immune cells to recognise and remove the amyloid protein, which builds up in the brains of people with Alzheimer's disease. The protein build-ups are thought to be toxic to brain cells, leading to the symptoms of Alzheimer's, the Alzheimer's society has said. Lecanemab can, however, cause swelling and bleeding in the brain. In trials for Donanemab, a third of recipients experienced abnormalities in their brain scans caused by brain swelling and bleeding, NICE said. The drugs reportedly cost around £20,000 to £25,000, with the NHS being offered a lower price. Privately, the treatment costs between £60,000-80,000 per year, according to Alzheimer's Research UK. In a previous review by NICE in October 2024, director of medicines evaluation Helen Knight said: 'Donanemab could slow down cognitive decline by 4-7 months, but this is just not enough benefit to justify the additional cost to the NHS. The cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources'. While the regulator said the decision would be disappointing for some, 'there are other treatments being developed'. Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said the decision to turn down the drugs would be 'deeply disappointing'. She added: 'These treatments are not perfect, and we recognise the challenges they pose around cost, delivery and safety. But scientific progress is incremental, and these drugs represent a vital foundation to build on.' The regulator NICE is due to publish the final draft guidance about the two drugs on Thursday. This leaves space for the decision to be challenged and sent to a review panel before the final guidance is published.
